...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection.
【24h】

Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection.

机译：白细胞介素28B基因型在近期丙型肝炎病毒感染的治疗决策中的潜在作用。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Polymorphisms in the IL28B (interleukin-28B) gene region are important in predicting outcome following therapy for chronic hepatitis C virus (HCV) infection. We evaluated the role of IL28B in spontaneous and treatment-induced clearance following recent HCV infection. The Australian Trial in Acute Hepatitis C (ATAHC) was a study of the natural history and treatment of recent HCV, as defined by positive anti-HCV antibody, preceded by either acute clinical HCV infection within the prior 12 months or seroconversion within the prior 24 months. Factors associated with spontaneous and treatment-induced HCV clearance, including variations in IL28B, were assessed. Among 163 participants, 132 were untreated (n = 52) or had persistent infection (infection duration >/=26 weeks) at treatment initiation (n = 80). Spontaneous clearance was observed in 23% (30 of 132 participants). In Cox proportional hazards analysis (without IL28B), HCV seroconversion illness with jaundice was the only factor predicting spontaneous clearance (adjusted hazards ratio = 2.86; 95% confidence interval = 1.24, 6.59; P = 0.014). Among participants with IL28B genotyping (n = 102 of 163 overall and 79 of 132 for the spontaneous clearance population), rs8099917 TT homozygosity (versus GT/GG) was the only factor independently predicting time to spontaneous clearance (adjusted hazard ratio = 3.78; 95% confidence interval = 1.04, 13.76; P = 0.044). Participants with seroconversion illness with jaundice were more frequently rs8099917 TT homozygotes than other (GG/GT) genotypes (32% versus 5%, P = 0.047). Among participants adherent to treatment and who had IL28B genotyping (n = 54), sustained virologic response was similar among TT homozygotes (18 of 29 participants, 62%) and those with GG/GT genotype (16 of 25, 64%, P = 0.884). Conclusion: During recent HCV infection, genetic variations in IL28B region were associated with spontaneous but not treatment-induced clearance. Early therapeutic intervention could be recommended for individuals with unfavorable IL28B genotypes.
机译：IL28B（白介素-28B）基因区域的多态性对于预测慢性丙型肝炎病毒（HCV）感染的治疗结局至关重要。我们评估了IL28B在最近的HCV感染后自发和治疗引起的清除中的作用。澳大利亚急性丙型肝炎试验（ATAHC）是一项针对近期HCV的自然病史和治疗的研究，其定义为阳性抗HCV抗体，然后在之前的12个月内进行了急性临床HCV感染，或者在过去的24个月内进行了血清转化几个月。评估与自发和治疗引起的HCV清除相关的因素，包括IL28B的变化。在163名参与者中，有132名在治疗开始时未接受治疗（n = 52）或持续感染（感染持续时间> / = 26周）（n = 80）。在23％（132名参与者中的30名）中观察到自发清除。在Cox比例风险分析中（无IL28B），HCV血清转化性疾病伴黄疸是预测自发清除的唯一因素（调整后的风险比= 2.86; 95％置信区间= 1.24、6.59; P = 0.014）。在具有IL28B基因分型的参与者中（自发清除人群中，n = 163，共163，132中的79），rs8099917 TT纯合性（相对于GT / GG）是唯一独立预测自发清除时间的因素（调整后的危险比= 3.78; 95） ％置信区间= 1.04，13.76; P = 0.044）。血清转化为黄疸的参与者比其他（GG / GT）基因型的rs8099917 TT纯合子更为常见（32％对5％，P = 0.047）。在坚持治疗且有IL28B基因分型的参与者中（n = 54），TT纯合子（29名参与者中的18名，62％）和GG / GT基因型参与者中的持续病毒学应答相似（25 of 16，64％，P = 0.884）。结论：在最近的HCV感染期间，IL28B区域的遗传变异与自发清除有关，而与治疗引起的清除无关。 IL28B基因型不良的个体可以建议早期治疗干预。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号